Trial Profile
Expanded Access Program of Pimavanserin in Patients With Parkinson's Disease Psychosis
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 18 Jul 2016
Price :
$35
*
At a glance
- Drugs Pimavanserin (Primary)
- Indications Parkinson's disease
- Focus Expanded access; Therapeutic Use
- Sponsors Acadia Pharmaceuticals
- 18 Jul 2016 New trial record